Cedar Hill Associates buys $20,540,466 stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Cedar Hill Associates scooped up 1,640 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 14, 2016. The investment management firm now holds a total of 141,327 shares of Thermo Fisher Scientific which is valued at $20,540,466.Thermo Fisher Scientific makes up approximately 3.54% of Cedar Hill Associates’s portfolio.

Thermo Fisher Scientific opened for trading at $145.42 and hit $146.6 on the upside on Monday, eventually ending the session at $146.47, with a gain of 0.78% or 1.13 points. The heightened volatility saw the trading volume jump to 9,07,628 shares. Company has a market cap of $58,040 M.

Other Hedge Funds, Including , Intermede Investment Partners Ltd boosted its stake in TMO in the latest quarter, The investment management firm added 56,931 additional shares and now holds a total of 212,409 shares of Thermo Fisher Scientific which is valued at $30,871,524. Thermo Fisher Scientific makes up approx 3.69% of Intermede Investment Partners Ltd’s portfolio.Consulta Ltd reduced its stake in TMO by selling 75,000 shares or 30.0% in the most recent quarter. The Hedge Fund company now holds 175,000 shares of TMO which is valued at $25,434,500. Thermo Fisher Scientific makes up approx 3.08% of Consulta Ltd’s portfolio.Central Bank Trust Co boosted its stake in TMO in the latest quarter, The investment management firm added 73 additional shares and now holds a total of 233 shares of Thermo Fisher Scientific which is valued at $33,864. Thermo Fisher Scientific makes up approx 0.01% of Central Bank Trust Co’s portfolio.First American Trust Fsb boosted its stake in TMO in the latest quarter, The investment management firm added 290 additional shares and now holds a total of 19,527 shares of Thermo Fisher Scientific which is valued at $2,766,195. Thermo Fisher Scientific makes up approx 0.98% of First American Trust Fsb’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.